A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

This is a Phase I safety trial of an experimental oral drug called QLC1101, which targets a specific cancer mutation called KRAS G12D. It is designed for patients with advanced solid tumors who have this mutation and for whom standard treatments have not worked. **You may be eligible if...** - You are 18 or older with advanced (metastatic or inoperable) solid tumor cancer - Your tumor has been confirmed to have a KRAS G12D mutation - Standard treatment options have failed, are unavailable, or you cannot tolerate them - You have at least one measurable lesion on imaging - Your general health score is 0 or 1 (fully active or able to do light work) - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have previously been treated with a KRAS G12D inhibitor - You have had another active cancer at the same time - You have serious lung, heart, or gastrointestinal conditions that could affect the drug - You are pregnant or could become pregnant without contraception Talk to your doctor to see if this trial is right for you.